The effects of activation of plasminogen by streptokinase and tissue-type-plasminogen activator on platelet activation and the membrane glycoproteins (GPs) that mediate platelet adhesion and aggregation are not yet fully defined. To clarify effects on platelets during activation of plasminogen in vitro, w e used monoclonal antibodies (MoAbs), flow cytometry, and platelets surface-labeled with lZ61 to characterize changes in receptors for fibrinogen (GPllb-llla), von Willebrand factor (GPlb), and collagen (GPla-Ha). Activation of plasminogen in plasma with pharmacologic concentrations of plasminogen activators did not degrade GPllb-llla or GPlb. and caused only a modest decrease in GPla. In washed platelets GPllb-llla was extensively degraded by LATELET ADHESION and aggregation are integral P events in the initiation of acute myocardial infarction (AMI) and modulate both the initial response to fibrinolytic therapy and the propensity for reocclusion after successful clot lysis.'-4 Inhibition of platelet aggregation accelerates initial clot lysis and delays or prevents reocclusion in animal models of thrombosi~.~*'~ The beneficial effects of adjunctive therapy with aspirin in clinical studies suggest that similar effects may occur in patients as we11."~'2 Despite evidence that inhibition of platelet function improves the success of fibrinolytic therapy, the extent to which activation of plasminogen directly activates platelets or degrades the surface glycoproteins (GPs) mediating platelet adhesion and aggregation has not been well defined.
Although there is evidence for platelet activation during thrombolysis in vivo, studies of the effects of plasmin on platelet function in vitro have yielded conflicting results."-16 Fibrinogen-dependent platelet aggregation and ristocetininduced platelet agglutination can be inhibited by plasmin, perhaps due to proteolysis of platelet-membrane-adhesive GPs. However, platelet inhibition in aggregometry studies may reflect the antiaggregatory effects of fibrinogen and von Willebrand factor (vWF) degradation products rather than direct plasmin-mediated proteolysis of platelet-surface receptors.''-l9 Because platelet dysfunction following thrombolytic therapy may contribute to bleeding complications, clarification of the circumstances under which pharmaco-logic activation of plasminogen directly degrades plateletadhesive receptors has direct clinical implications.' In addition, since platelet activation during fibrinolytic therapy may be due to factors other than the direct action of plasmin on platelets, it is important to determine whether activation of plasminogen directly activates platelets. '8-27 Accordingly, the present study was designed to characterize the direct effects of pharmacologic activation of plasminogen on the platelet-surface GP receptors involved in platelet adhesion and aggregation. This was accomplished by analysis of the binding of monoclonal antibodies (MoAbs) specific for these receptors with flow cytometry, and by definition of alterations in platelet-membrane adhesive GPs with platelets surface-labeled with Iz5I. Specifically, the effects of activation of plasminogen by pharmacologic and suprapharmacologic concentrations of streptokinase (SK) and tissue-type plasminogen activator (t-PA) were characterized for the platelet-fibrinogen receptor (GPIIb-IIIa), the vWF receptor (GPIb), and the collagen receptor (GPIa-IIa).
Our results suggest that minimal plasmin-mediated proteolysis of these platelet-adhesive receptors occurs after pharmacologic activation of plasminogen in plasma.28 In addition, flow cytometry studies performed with activation-specific MoAbs show no evidence of direct platelet activation during activation of plasminogen with t-PA or SK. However, in washed platelet preparations, degradation of GPIIb-IIIa and GPIb by plasmin is dependent on both temperature and the absence of added Caz+.
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human plasmin were purchased from KabiVitrum. All other reagents were from Sigma (St Louis, MO).
Platelets were obtained from normal volunteers who gave written informed consent and were not taking any medications known to interfere with platelet function. Antecubital venipuncture was performed with a 19-gauge needle after application of a light tourniquet. Whole blood was anticoagulated with either 1/10 vol of 3.8% (wt/vol) trisodium citrate, pH 7.4, or acid citrate dextrose (ACD, 0.038 mol/L citric acid, 0.075 mol/L trisodium citrate, 0.14 mol/L a-D-glucose), pH 4.5. Heparin sodium (1 U/mL) or ethylenediaminetetraacetic acid (EDTA, 10 mmol/L) was used for anticoagulation in several studies. Neither ACD nor EDTA was used in experiments designed to assess the effects of activation of plasminogen or platelet activation. Platelet-rich plasma (PRP) was isolated after centrifugation of anticoagulated whole blood at l5Og for 15 minutes. For some studies autologous plateletpoor plasma was prepared by centrifuging citrated PRP at 1500g for 10 minutes.
To prepare washed platelets for flow cytometry studies, an additional 1/10 vol of ACD and PGE, (10 pmol/L) were added to the PRP, and the platelets were pelleted at 1,500g for 10 minutes. Platelets were resuspended in 20 mL of washing buffer (0.14 mol/L NaCI, 2.7 mmol/L KCI, 12 mmol/L NaHCO,, 0.5 mmol/L Na,P04, 5.5 mmol/L a-D-glucose, 5.0 mmol/L N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid [HEPES], 1/10 vol ACD, IO pmol/L PGE,, pH 6.5, [Tyrode-HEPES wash buffer]) and centrifuged at 1,500g for 10 minutes. The initial wash was repeated and the platelets were resuspended in TyrodeHEPES buffer (no ACD or PGE,, no divalent cations), pH 7.4. For specific experiments 2 mmol/L CaCI, was added as described.
For studies with platelets surface-labeled with "'I, platelets were pelleted from PRP as described above and washed twice by centrifugation with 20 mL of the following buffer: 0.15 mol/L NaCl, 0.05 mol/L Tris, 1/10 vol ACD, 10 pmol/L PGE,, and 5.5 mmol/L a-D-glucose, pH 6.5 (TBS wash buffer). Platelets were then resuspended in TBS wash buffer and surface-labeled with "'I by the lactoperoxidase method." Surfacelabeled platelets were then washed two more times by centrifugation with TBS washing buffer and resuspended in autologous citrated plasma or Tyrode-HEPES buffer (no ACD or PGE,), pH 7.4. Incubations in buffer were performed in the presence or absence of 2 mmol/L CaCl,.
Plasminogen was activated in citrated PRP with pharmacologic and suprapharmacologic concentrations of SK (1,000 or 20,000 U/mL) or t-PA (2.5 or 20 pg/mL). For studies of platelets surface-labeled with Iz5I, the platelets were resuspended in autologous platelet-poor plasma. Washed platelets were incubated with the same doses of SK or t-PA in Tyrode-HEPES buffer supplemented with 21 pg/mL of human plasminogen in the presence or absence of 2 mmol/L CaCl,. Control incubations included plasminogen and a matched volume of t-PA (0.2 mol/L arginine phosphate, pH 7.2) or SK (0.9% NaCI) buffer. In studies of both washed platelets and PRP, activation of plasminogen was accomplished at 23O or 37OC for up to 60 minutes. The platelet count was 1 to 2 x 108/mL during incubations with plasminogen activators.
In studies of platelets surface-labeled with '"I, incubations were terminated by the addition of 5 pmol/L PPACK and 200 KIU/mL aprotinin. After 10 minutes, 1/10 vol ACD was added and the platelets were pelleted for 2 minutes at 12,OOOg. The supernatant was removed by aspiration and the platelet pellet was dissolved by boiling for 10 minutes in electrophoresis gel buffer (0.063 mol/L Tris, 2% SDS, 10% glycerol, 0.001% wt/vol bromphenol blue) with or without 1.0% 2-mercaptoethanol. Samples were analyzed on 6% polyacrylamide gels (SDS-PAGE) by the method of Laemmli.M The gels were dried under vacuum and autoradiography was performed with X-omatic AR-5 film and an imageintensifier screen (Kodak,
Preparation of platelets.
Rochester, NY). Gels were developed after 4 to 7 days at -70%. Major platelet GP bands were analyzed by use of a laser densitometer (LKB 2400, Bromma, Sweden).
Results obtained with '*'I surface-labeled platelets during pharmacologic activation of plasminogen in citrated plasma were compared to similar autoradiographic studies performed with platelets obtained at hourly intervals from a patient receiving 100 mg of t-PA for AMI.
Platelet-surface GP degradation was quantitated by the use of FITC-labeled MoAbs and analysis of their binding to specific receptors by flow cytometry. MoAb 10E5, a complex specific antiXPIIb-IIIa antibody, was a gift of B. Coller (State University of New York, Stonybrook).".'* MoAb 6D1 (B. Coller) binds to the glycocalicin portion of GPIb." MoAb 12F1 binds to the GPIa subunit of GPIa-IIa (gift of V. Woods, University of California, San Dieg~).'~.'~ MoAbs specific for platelet activation were PAC1, which binds to the activated GPIIb-IIIa complex (gift of S. Shattil, University of Pennsylvania, Philadel~hia),'~"~ and S12, which recognizes the a granule protein (GMP-140 or PADGEM) expressed on the platelet surface after platelet secretion (gift of R.
McEver, University of Oklahoma, Tulsa).4042 For flow cytometry MoAbs 10E5,6D1,12Fl,andS12 wereusedata finalconcentration of 5 to 10 pg/mL. MoAb PACl was used at 9 to 18 pg/mL.
Before Fluorescein isothiocyanate ( FITC) labeling, MoAbs were dialyzed overnight at 4OC in 0.1 mol/L NaH,PO,, pH 7.4. FITC stock was prepared immediately before use at 0.8 mg/mL in 0.5 mol/L Na,CO,, pH 9.5. FITC stock was added to MoAb at 1:5 (wt/wt), the pH was readjusted to 9.5, and the incubation was allowed to proceed at 23OC for up to 2 hours with intermittent vortexing. The peak corresponding to labeled MoAb was separated from free FITC on a 30.0 x 0.5 cm Sephadex G-25-300 (Pharmacia, Uppsala, Sweden) gel filtration column equilibrated with 0.1 mol/L NaH,P04.
For flow cytometry studies platelets were incubated with t-PA or SK in citrated plasma or buffer in the presence of plasminogen as described above. After 60 minutes, 50-pL aliquots of platelets were removed and added to Tyrode-HEPES buffer, PPACK ( 5 pmol/L), aprotinin (200 KIU/mL), and FITC-MoAb at 23OC in a final volume of 200 pL. When calcium had been omitted from washedplatelet incubations it was added to a final concentration of at least 100 pmol/L during incubation with MoAbs before flow cytometry. After a 30-minute incubation, flow cytometric analysis was performed by use of a Coulter Epics model 753 flow cytometer (Hialeah, FL) with a 250-mW argon laser emitting at 488 nm. Fluorescence emission was detected at 525 nm with a band pass filter. Platelets were distinguished from cellular fragments by their characteristic forward-and side-light scatter, and a gate was set to analyze the fluorescence from single platelets. The bound fluorescence from 25,000 platelets was analyzed and plotted as a histogram of platelet number versus fluorescence intensity per platelet. The fluorescence scale extends over a 3-decade log scale divided into 256 equal channels. At the gain settings used, 295% of nonspecific binding fell in the first 15 channels. For the activation-specific MoAbs PACl and S12, activated platelets were defined as those whose fluorescence fell above channel 15. For quantitation of changes in GPs Ib, IIb-IIIa, and Ia-IIa the mean population fluorescence channel number was calculated with on-line software. Mean fluorescence channel number was converted from log to linear format.
Blood samples were also obtained from patients receiving t-PA (100 mg) for AMI. Plasmin was inhibited with PPACK ( 5 pmol/L) and aprotinin (1,000 KIU/mL) and PRP obtained as described above. Binding of FITC-MoAbs 10E5 (anti-GPIIb-IIIa) and 6D1 (anti-GPIb) to platelets was quantitated by flow cytometry. All patient samples for flow cytometry and autoradiographic studies Activation of plasminogen was performed in plasma or buffer as described. After 60 minutes aliquots were removed and the platelets were pelleted at 1 2 . 0 0 0~ for 2 minutes. The supmatant was collected and immediately froten at -7OOC. Samples were thawed and diluted 120 with 0.1 I mol/l. NaCI.0.05 mol/l. Tris. pH 7.4. and added to the wells of a microtiter plate (Costar. RioRad. Richmond. CA). The chromogenic substrate for plasmin activity. S-2251." was added to a final concentration of 312 pmol/L. Activity of purified human plasmin was used to develop a standard curve from 0.0025 to 0.02 caseinolytic units (CW) per milliliter. The change in absorbance due to hydrolysis of the substrate was measured every 20 seconds for 6 minutes with a programmable automated kinetic plate reader at 23% (Molecular Dcvices. Menlo Park. CA). The lower limit of detectibility for samples assayed with a I:20 dilution was 0.05 CU/mL plasmin activity. The human plasminogen preparation exhibited no plasmin activity in this assmy.
cr-2-Antiplasmin was measured in PRP with an assay based on the plasmin-specific chromogenic sub~trate S-2251 a s modified from the manufacturer's instructions for use with microtiter plates (KabiVitrum). Plasmin was added to samples in e x m c and residual plasmin activity against the subsrrate S-2251 was measured with the automated kinetic plate reader. cr-2-Antiplasmin levels were derived by comparison with a standard curve developed with serial dilutions of pooled human plasma. platelets were compared by paired analysis through UK of the IVilcoxon signed-rank method. and a significant difference was considered to exist when P < .05.
RESULTS

Ffects on GPs after activation of plasminogen in plasma.
To characterize structural changes in membrane GPs, platelets surface-labeled with "' I wcre suspended in autologouscitrated plasma and incubated with t-PA or S K for up to 60 minutes at 37OC. The migration of platelet GPs Ibn. Ilk. and 1113 as determined by reduced 6 7 SDS-PAGE was unchanged aftcr incubation with pharmacologic concentrations of I-PA (2.5 pg/mL) or SK (I.OO0 C/mL. Fig I) . Similar results were obtained with incubations at 23OC (data not shown). With suprapharmacologic conccntrations of t-PA (20.0 pg/mL) and SK (20.000 L/mL) there was some proteolysis of minor CPs migrating above GP Ibn. but the migrations of GPs Ibn. Ilbcr. and Illa remained unchanged (Fig I) . However. with 1-PA (20 pg/mL) densitometry demonstrated a mean decrease of 30% in the GPlbn band at 60 minutes (n = 2). The degradation of GPlbn observed with suprapharmacologic concentrations of t-PA did not appear to be a function of plasmin activity alone. a s S K generated higher plasmin acrivity in plasma than t-PA (Table I ) . As expected, cr-2-antiplasmin was depleted during incubations with I-PA o r SK in PRP (data not shown). 
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For personal use only. on August 30, 2017. by guest www.bloodjournal.org From Plasmin activity against the chromogenic substrate $225 1 after activation of plasminogen with t-PA or SK in citrated plasma or buffer. Mean 5 SEM (n = 8 to 18).
GPs Iba, IIba, and IIIa after activation of plasminogen in PRP with pharmacologic concentrations of t-PA or SK (Fig  2) . Binding of MoAb 10E5 (anti-GPIIb-IIIa) to platelets did not decrease compared with control after incubation with both pharmacologic and suprapharmacologic concentrations of t-PA or SK, as indicated by a lack of change in relative mean fluorescence (Fig 2A) . Similar results were obtained with MoAb 6D1 (anti-GPIb), although there was a trend toward decreased MoAb 6D1 binding with 20 pg/mL of t-PA that failed to achieve significance (P = .07, Fig 2B) . Binding of MoAb 12F1, which binds to the Ia subunit of GPIa-IIa, did not change after incubation with t-PA, although modest decreases in binding of 15% to 20% occurred after SK (P = .03, Fig 2C) . Examination of individual histograms of platelet number versus fluorescence per platelet did not show any distinct subpopulations of platelets deficient in the GP receptors characterized with MoAbs 10E5, 6D1, or 12F1. In contrast to the findings at 37OC, results of flow cytometric studies of platelets incubated in plasma with pharmacologic and suprapharmacologic concentrations of t-PA or SK at 23OC demonstrated no decrease in the binding of MoAb 10E5,6D1, or 12F1 (data not shown).
Eyects on GP IIb-IIIa after activation of plasminogen in buyer. To characterize the effects of plasminogen activation in a purified system, platelets surface-labeled with Iz5I were incubated at 37OC with 1,000 U/mL of SK in divalent cation-free Tyrode-HEPES buffer supplemented with 21 pg/mL of human plasminogen. Analysis of autoradiograms from control platelets incubated in the absence of SK demonstrated no change in GP IIb-IIIa on either reduced or nonreduced gels (Fig 3) . In contrast, activation of plasminogen with SK produced striking degradation of GPs IIb and IIIa (Fig 3) . Proteolysis was evident by 10 minutes, with the subsequent generation of three new fragments with apparent mol wts of 78, 71, and 66 Kd on 6% SDS-PAGE under nonreducing conditions. Reduced SDS-PAGE confirmed the proteolysis of GPs IIba and IIIa, with degradation fragments migrating as a broad band with a mol wt of 65,000 to 70,000 (Fig 3) .
Previous studies have demonstrated dissociation of GPIIbIIIa at 37OC in the presence of strong Ca2+-chelating agent^:^.^^ To determine whether the presence of Ca2+ or the incubation temperature affected the proteolysis of GPIIb or IIIa in a purified system, incubations of surface-labeled platelets with 2.5 pg/mL of t-PA were performed under the following conditions: 23°C without added Ca2+, 37OC without added Ca2+, and 37OC with 2 mmol/L Ca2+ (Fig 4) . Control incubations in the absence of plasminogen activators at 23O and 37OC with or without Ca2+ demonstrated no change in the migration of GPs IIba and IIIa. At 23OC in the absence of added Ca2+, GPIIb-IIIa was resistant to plasminmediated proteolysis (Fig 4) . At 37OC in the presence of Ca2+, GPIIIa was resistant to proteolysis while GPIIba underwent a modest degradation. However, activation of plasminogen with 2.5 pg/mL of t-PA at 37OC in the absence of added Ca*+ resulted in almost complete degradation of both GPs IIba and IIIa (Fig 4) . Marked proteolysis was evident despite generation of only 0.08 +_ 0.01 CU/mL of plasmin activity with 2.5 pg/ml, of I-PA in washed-platelet prcparations (Table I ) For (Figs 5 and 6C) . Loss of MoAb 10E5 binding in the absence of t-PA or SK at 37OC without the presence of added Ca2+ was detectable as early as 15 minutes, which corresponded to the time course of plasmin-mediated degradation of GPIIb-IIIa when analyzed by SDS-PAGE and autoradiography (Figs 3 and 4) . Because the migration of GPs IIb and IIIa as detected by SDS-PAGE was unchanged in the absence of t-PA or SK at 37OC without added Ca2+ (Figs 3  and 4) , the decrease in MoAb 10E5 binding with flow cytometry suggested a conformational change in GPIIb-IIIa, leading to loss of the complex specific epitope recognized by this antibody. Indeed, activation of plasminogen by t-PA or SK at 37OC in the absence of exogenous Ca2+ produced only an additional 5% to 10% decrease in MoAb 10E5 binding, suggesting that the small number of GP IIb-IIIa complexes that retain native conformation under these conditions are relatively resistant to degradation (Fig 6C) . In contrast, activation of plasminogen at 23OC in the absence of Ca2+ or at 37OC in the presence of added Ca2+, conditions that maintain the integrity of the IIb-IIIa complex, produced only small decreases in MoAb 10E5 binding (Fig 6A and B) .
Effects on GPs Ib and la after activation of plasminogen in buffer. To determine whether GPIb displayed a similar temperature-and Ca2+-dependent susceptibility to plasminmediated proteolysis, washed platelets surface-labeled with "' I were incubated with t-PA or SK in Tyrode-HEPES buffer in the presence of plasminogen. Densitometric analysis of autoradiograms from platelets incubated with either t-PA (2.5 pg/mL) or SK (1,000 U/mL) at 37OC in the absence of Ca2+ demonstrated a 50% decrease in GPIb by 60 minutes (Figs 3 and 4) . At 23OC in the absence of Ca2+, activation of plasminogen with 2.5 pg/mL of t-PA produced no change in GPIba (Fig 4) , while incubation at 37OC in the presenceof Ca2+ resulted in a 30% loss of GPIba (Fig 4) . The temperature and Ca2+-dependent proteolysis of GPIb was most striking with 20 pg/mL of t-PA (Fig 7) . Activation of plasminogen with suprapharmacologic concentrations of t-PA produced a 60% loss of GPIba at 23OC in the absence of Ca2+, a 75% loss at 37OC in the presence of Ca2+, and a 90% decrease at 37OC in absence of added Ca2+ (Fig 7) . A similar though less marked temperature-and Ca2+-dependent proteolysis of GPIb occurred with 20,000 U/mL of SK (Fig 7) .
Binding of MoAb 6D1 (anti-GPIb) as analyzed by flow cytometry remained stable when platelets were incubated for up to 60 minutes in Tyrode-HEPES buffer with plasminogen (21 pg/mL) in the absence of t-PA or SK, regardless of temperature or Ca2+ conditions (Fig 8) . Activation of plasminogen with pharmacologic concentrations of t-PA produced no change in the binding of MoAb 6D1, regardless of temperature or Ca2+ conditions (Fig 8) . Incubations with SK (1,000 U/mL) at 37OC in the absence of Ca2+ produced a 30% decrease in MoAb 6D1 binding, but this change was not significant by paired analysis (P = .07, Fig 8C) . Incubations of washed platelets with 20 pg/mL of t-PA resulted in a 50% decrease in MoAb 6D1 binding at 37OC in the absence of added Ca2+ (P = .04). The results of autoradiography and flow cytometry suggest that GPIb may undergo partial proteolysis in washed platelets while binding of MoAb 6D1, an antibody that binds close to the ligand-binding domain of GPIb, is preserved. Another explanation for the discrepancy between the magnitude of GPIb degradation on autoradiography and the amount of MoAb 6D1 binding on flow cytometry may be the replacement of degraded receptors from the internal platelet pool of GPIb.so*5' However, both autoradiographic and flow-cytometric studies demonstrate the temperature-and Ca2+-dependence of GPIb degradation by plasmin (Figs 4,7, and 8) .
In contrast to the findings with GPs IIb-IIIa and Ib, there was no evidence of a decrease in MoAb 12F1 (anti-GP Ia) binding to washed platelets during activation of plasminogen with t-PA or SK at 23OC or 37OC in the presence or absence of Ca2+ (data not shown).
Although our observations in citrated plasma demonstrate that platelet-adhesive GP degradation does not occur following activation of plasminogen with pharmacologic concentrations of t-PA or SK (Figs 1 and 2) , it is conceivable that prolonged platelet exposure to activation of plasminogen in vivo may result in proteolysis of platelet receptors. To examine this possibility, platelets were obtained from patients receiving a 3-hour infusion of t-PA (100 mg) for AMI. Platelets from one patient were surfacelabeled with 12'1 and subjected to SDS-PAGE and autoradiographic analysis. At 2 and 4 hours after initiation of t-PA there was no change in the amount of platelet" surface GPs Ib, IIb, and IIIa, compared with platelets obtained before fibrinolytic therapy, despite substantial proteolysis of platelet surface-associated fibrinogen (Fig 9) . In addition, flowcytometric analysis of platelets from an additional five patients demonstrated no change in the binding of FITCMoAbs 10E5 (anti-GPIIb-IIIa) and 6Dl (anti-GPIb) following t-PA therapy for AMI.
Activation-specijc MoAbs during activation of plasminogen in plasma. Platelets were incubated in citrated plasma at 37OC with pharmacologic and suprapharmacologic concentrations of t-PA or SK for periods of up to 1 hour. The binding of PACl, an MoAb that binds to the GPIIb-IIIa fibrinogen receptor on platelets after activation, did not increase when platelets were incubated with either t-PA or SK, consistent with a lack of platelet activation in response to activation of plasminogen (Fig 10) . Even after incubation with 20,000 U/mL of SK there was no evidence of platelet activation or aggregation (P > .3, n = 9, despite the generation of substantial plasmin activity of 0.87 f 0.08 CU/mL, a level comparable with that reported to induce platelet activation by others." Platelets incubated with t-PA or SK in plasma could still be activated with 10 pmol/L ADP, as evidenced by an ADP-induced increase in PACl binding comparable to that observed with control platelets (Fig 10) . The absence of platelet activation in citrated plasma during activation of plasminogen was confirmed by the lack of increased binding of MoAb SI2 documented with flow cytometry. This antibody binds to the a granule protein (GMP-140), which is expressed on the platelet surface after platelet secretion.
DISCUSSION
Our results indicate that activation of plasminogen in citrated plasma by pharmacologic concentrations of t-PA or SK does not result in degradation of platelet adhesive receptors for fibrinogen and WF. Although some degradation of the collagen receptor occurs in plasma with SK, it is modest. However, plasmin-mediated proteolysis of GPIlbIIIa in washed platelets is marked a t physiologic temperatures in the absence of added Ca2+. Similarly, plasminmediated degradation of GPIb in washed platelets is increased a t physiologic temperatures, in the absence of added Ca2+, in the presence of increased plasmin activity, and with suprapharmacologic concentrations of t-PA. Furthermore, we could not find any evidence that activation of plasminogen in citrated plasma by t-PA or SK directly activates platelets. Consequently, the platelet activation observed during pharmacologic activation of plasminogen does not appear to result from the direct action of plasmin on platelet^.'^.'^ In addition, the resistance of platelet-adhesive receptors to plasmin-mediated degradation in plasma suggests that the inhibition of platelet aggregation in plasma observed by others is most likely due to factors other than the proteolysis of GPs, Ib, IIb, and IIIa.I7-I9
Previous studies of platelet function have indicated that activation of plasminogen in plasma can induce both antiaggregatory and proaggregatory response^.'^-^^^'^ Antiaggregatory effects may be due to generation of fibrinogendegradation products that compete with fibrinogen for binding to the platelet GPIIb-IIIa fibrinogen receptor but do not support platelet aggregatiom2' In addition, proteolysis of W F by plasmin may explain the inhibition of ristocetin-induced platelet aggl~tination.'.'~ Although antiaggregatory effects GP receptors (as shown by SDS-PAGE during activation of plasminogen in plasma) suggest that the fibrinogen and vWF receptors arc likely to retain function. The observation of Loscalzo and Vaughan that platelets disaggregated by suprapharmacologic concentrations of I-PA in plasma could be reaggregated by ADP if resuspended with intact fibrinogen is consistent with functional competence of the GPllb-llla receptor after activation of plasminogen in plasma." Degradation of platelet surface GPllb-llla has been reported in washed platelets during activation of plasminogen with t-PA.'"Our finding that GPllb-llla is not degraded in association with activation of plasminogen in plasma suggests that the results obtained in washed-platelet systems ma); not be extrapolated to explain antiaggregatory effects in plasma. In addition. degradation of GPllb-Illa in washed platelets in the absencc of Ca" may explain discordant observations in studies of washed platelets and platelets in plasma. Irreversible dissociation of GPllb-llla can be induced by incubation of washed platelets at 37OC with strong Ca' ' -chelating agents such as EDTA.""" Chelation of Ca' ' at 23°C docs not result in dissociation of GPllb-llla at physiologic pH." "suggesting that both physiologic temperature and the absence of Ca" are required to induce instability of the Ilb-llla complex. We have shown that as few as two washes in ACD-containing buffer are sufficient to destabilize GPllb-llla when platelets are subsequently incu-
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bated at 37OC in the absence of added Ca?'. Under these conditions. even in the absence of plasmin. the results of SDS-PAGE and autoradiography demonstrate that GPllb and llla polypeptides are still present on the platelet surface but that VoAb IOE5 will no longer bind to the Ilb-llla complex. even following restoration of Ca" before incubation with the antibody. In addition. the dissociated GPllbllla receptors on platelets in buffer at 37OC in the absenceof Ca-" are exquisitely sensitive to plasmin-mediated dcgradation. Marked degradation occurred with plasmin activity less than 0.1 CU/mL. However. at 37OC in the presence of exogenous Ca". binding of the complex specific MoAb IOES to the Ilb-llla complex is maintained even when platelets arc incubated with suprapharmacologic doses of I-PA or S K in the presence of plasminogen. Recently Beer and Coller have reported susceptibility of GPllla to proteolysis by plasmin and other proteases on washed platelets in the presence of EDTA. although temperature conditions were not specified." Our observations arc in agreement with theirs and suggest that plasmin can degrade both GPllb and llla in the abwnce of Ca-" at 37°C. However. our results also demonstrate that the GPllb-llla does not undergo significant plasminmediated proteolysis in the presence of Ca-" .
Proteolysis of platelet GPlb has also been reported in washed platelets incubated with plasmin and with I-PA in the presence of plasminogen.""' Although the function of GP Ib does not require the presence of divalent cations." our observations in washed platelets suggest that it is more susceptible to plasmin-mediated degradation at 37OC in the absence of Ca". I n incubations without plasminogen activators the binding of MoAb 6DI is maintained regardless of temperature or Ca" conditions. This argues against a major change in theconformationofGPlbat 37OC in theabsenceof Ca". However. the increased proteolysis of GPlb at 37OC in For personal use only. on August 30, 2017. by guest www.bloodjournal.org From the absence of Ca" suggests that subtle changcs in the conformation of GPlb or changcs in its microenvironment under these conditions render GPlb more susceptible to proteolysis by plasmin.
We also observed a discrepancy between the degrcc of GPlb degradation in washed platelets determined by SDS-PAGE and autoradiography and MoAb 6D1 binding with flow cytometry. For example, activation of plasminogen with I-PA (2.5 &mL) at 37°C in the absence of addcd Ca" rcsultcd in a decrease in GPlb on autoradiography (Fig  4) . while similar incubations caused no change in MoAb 6DI binding on now cytometry (Fig 8 ) . This suggcsts that GPlb receptors degraded by plasmin may be replaced by intact receptors from the internal platelet p o l of GPlb dcscribcd by Michelson et al and others.'' However. we could detect no decrease in "'I surface-labeled GPlb during activation of plasminogen in plasma with pharmacologic concentrations of t-PA and SK (Fig I ) . Preliminary patient studies during fibrinolytic therapy for A M I have yielded discordant results."'" Administration of t-PA raulted in a small increase in platelet surface GPlb. with a concomitant 197 decrease in total platelet GPlb, compatible with replacement of degraded GPlb rcccptors from the internal platelet pol."
In contrast, SK therapy for A M I produced a 1 9~d e c r~i s e in surface GPlb but no change in GPllla." Our autoradiographic-and flow cytometric patient studics suggest that the amount of platelet surface GPs Ib, Ilb, and llla docs not change during infusion of I-PA, although the psqibility of continuous replacement of degraded GPlb receptors in vivo cannot be excluded by this method.
These discordant results will require further clinical study. but presently the following conclusions appear warranted from our observations and previous studies. First. GPlb is readily hydrolyzed on washed platelets by high doscs of plasmin.'*,'' Second. proteolysis of GPlb on washed platelets can be enhanced by physiologic temperatures and chelation of Ca". Third, degradation of GPlb is modcst in plasma during activation of plasminogen by pharmacologic concentrations of plasminogen activators and may be offset by replacement of degraded receptors from internal platelet st~res.'~~'' Finally, in view of the resistance of GPIb to plasmin-mediated proteolysis in plasma, the marked inhibition of ristocetin-induced platelet agglutination described by others following activation of plasminogen in plasma is likely due to factors other than the degradation of GPIb.17- '9 Although small decreases in MoAb 12F1 binding to GPIa were seen with SK in plasma, generally GPIa was resistant to degradation in both plasma and washed-platelet studies. Because MoAb 12F1 does not block collagen binding to GPIa-IIa, it is possible that plasmin-mediated degradation of the collagen binding site of GPIa-IIa may occur. Because GPIa is difficult to locate consistently on one-dimensional SDS-PAGE studies, definitive conclusions concerning the effects of plasmin on Mg2+-dependent platelet adhesion to collagen will require functional assays and perhaps the use of MoAbs that inhibit the function of GPIa-IIa.
Fitzgerald et a1 have demonstrated elevated levels of thromboxane metabolites indicative of platelet activation during plasminogen activation with SK and t-PA.43'32'4 However, activation of platelets in vivo may result from other factors, such as release of thrombin from clot,2' re-exposure of collagen in the ruptured atherosclerotic p l a q~e ,~~. '~ a procoagulant surface on the residual or direct procoagulant effects attributable to plasmin interactions with the clotting ~y s t e m .~~. '~ We found no increase in the binding of MoAb PAC 1, which specifically recognizes the GPIIb-IIIa -0 JI FLUORESCENCE CHANNEL NUMBER complex on activated platelets, or MoAb S12, which binds to the a granule protein (GMP-140) expressed on the platelet surface after platelet secretion, demonstrating the absence of direct activation of platelets during activation of plasminogen in citrated plasma.
In conclusion, while GPIIb-IIIa, and to a lesser extent GPIb, can be degraded by plasmin in purified systems in the absence of Ca2+, these receptors are preserved during pharmacologic activation of plasminogen in plasma. Our observations suggest that functional impairment of the major plateletadhesive receptors is unlikely to occur during activation of plasminogen in plasma. Thus, platelets in patients treated with fibrinolytic agents appear to retain the necessary complement of surface receptors required to mediate coronary reocclusion after successful fibrinolytic therapy.57 The mechanisms for platelet activation and impaired platelet function during pharmacologic thrombolysis remain undefined, but they appear to result from effects of activation of plasminogen on plasma components rather than direct effects on platelets. 
